MedTrace Logo

Assessing Ketorolac (Toradol) at Oocyte Retrieval

NCT06026553 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2023-09-07

No results posted yet for this study

Summary

To determine if a nonsteroidal anti-inflammatory drug (NSAID), Ketorolac (Toradol), can improve pain control and decrease narcotic use after undergoing egg retrieval.

Conditions

  • Infertility
  • Infertility, Female
  • Oocyte Retrieval
  • Postoperative Pain
  • Embryo Transfer

Interventions

DRUG

Ketorolac (Toradol)

IV Ketorolac (Toradol) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.

OTHER

Placebo (saline)

IV Placebo (saline) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.

Sponsors & Collaborators

  • Shady Grove Fertility Reproductive Science Center

    lead OTHER

Principal Investigators

  • Kathleen Devine, MD · Shady Grove Fertility Reproductive Science Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-10
Primary Completion
2023-12-31
Completion
2025-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06026553 on ClinicalTrials.gov